Effects of tamoxifen on nitric oxide synthesis and neoplastic transformation in C3H 10T1/2 fibroblasts

Cancer Letters

Volumn 122, Issue 1-2, 1998, Pages 67-75

  Loo, Sandra A ^a   Lesoon Wood, Leslie A ^a   Cooney, Robert V ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

Carcinogenesis; Nitric oxide; Tamoxifen; Transforming growth factor

Indexed keywords

3 METHYLCHOLANTHRENE; ANTIESTROGEN; BACTERIUM LIPOPOLYSACCHARIDE; GAMMA INTERFERON; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL STIMULATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; FIBROBLAST; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; VIRUS CELL TRANSFORMATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; ESTROGEN ANTAGONISTS; MICE; MICE, INBRED C3H; NITRIC OXIDE; TAMOXIFEN;

ANIMALIA; BACTERIA (MICROORGANISMS); MURINAE;

EID: 0032498257     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)00373-X     Document Type: Article

References (39)

1. Fisher B., Redmond C. New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J. Natl. Cancer Inst. 83:1991;1278-1281.
2. Nayfield S.G. Tamoxifen's role in chemoprevention of breast cancer: an update. J. Cell. Biochem. 22:1995;42-50.
3. H. Wiseman, An overview of the clinical use of tamoxifen in the treatment and prevention of breast cancer, in: Tamoxifen: Molecular Basis of Use in Cancer Treatment and Prevention, Wiley, London, 1994, pp. 36-37.
4. Williams G., Latropoulos M.J., Djordjevic M.V., Kaltenberg O.P. The triphenylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis. 14:1993;315-317.
5. King C.M. Tamoxifen and the induction of cancer. Carcinogenesis. 55:1995;1449-1454.
6. DeGregorio M.W. Is tamoxifen chemoprevention worth the risk in healthy women? J. Natl. Inst. Health Res. 4:1992;84-87.
7. Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43:1991;109-142.
8. Wink D.A., Kasprazak K.S., Maragos C.M., Elespuru R.K., Misra M., Dunams T.M., Cebula T.A., Koch W.H., Andrews A.W., Allen J.S., Keefer L.K. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science. 254:1991;1001-1003.
9. Xiao L., Eneroth P.H.E., Qureshi G.A. Nitric oxide synthase pathway may mediate human natural killer cell cytotoxicity. Scand. J. Immunol. 42:1995;505-511.
10. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329:1993;2002-2012.
11. Nguyen T., Brunson D., Crespi C.L., Penman B.W., Wishnok J.S., Tannebaum S.R. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc. Natl. Acad. Sci. 89:1992;3030-3034.
12. Wei X.-Q., Charles I.G., Smith A., Ure J., Feng G.-J., Huang F., Xu D., Muller W., Moncada S., Liew F.Y. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature. 375:1995;408-411.
13. Nelson R.J., Demas G.E., Huang P.L., Fishman M.C., Dawson V.L., Dawson T.M., Snyder S.H. Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. Nature. 378:1995;383-386.
14. Hasan K., Heesen B.-J., Corbett J.A., McDaniel M.L., Chang K., Allison W., Wolffen-Buttel B.H.R., Williamson J.R., Tilton R.G. Inhibition of nitric oxide formation by guanidines. Eur. J. Pharmacol. 249:1993;101-106.
15. Saltzman B.E. Colorimetric micro-determination of nitrogen dioxide in the atmosphere. Anal. Chem. 26:1954;1949-1954.
16. Mordan L.J., Burnett T.S., Zhang L.-X., Tom J., Cooney R.V. Inhibitors of endogenous nitrogen oxide formation block the promotion of neoplastic transformation in C3H 10T1/2 fibroblasts. Carcinogenesis. 14:1993;1555-1559.
17. Reznikoff C.A., Brankow D.W., Heidelberger C. Establishment and characterization of a cloned line of C3H mouse embryo cells sensitive to post-confluence inhibition of division. Cancer Res. 33:1973;3231-3238.
18. Cooney R.V., Pung A., Harwood P.J., Boynton A.L., Zhang L.-X., Hossain M.Z., Bertram J.S. Inhibition of cellular transformation by triphenylmethane: a novel chemopreventive agent. Carcinogenesis. 13:1992;1107-1112.
19. Nathan C., Xie Q.-W. Regulation of biosynthesis of nitric oxide. J. Biol. Chem. 269:1994;13725-13728.
20. Bertram J.S., Pung A., Churley M., Kappock IV T.J., Wilkins L.R., Cooney R.V. Diverse carotenoids protect against chemically induced neoplastic transformation. Carcinogenesis. 12:1991;671-678.
21. Langan-Fahey S., Tormey D.C., Jordan V.C. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur. J. Cancer. 26:1990;883-888.
22. Arroyo P.L., Hatch-Pigott V., Mower H.F., Cooney R.V. Mutagenicity of nitric oxide and its inhibition by antioxidants. Mutat. Res. 281:1992;193-202.
23. Wink D.A., Hanbauer I., Krishna M.C., DeGraff W., Gamson J., Mitchell J.B. Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc. Natl. Acad. Sci. USA. 90:1993;9813-9817.
24. Yang W., Ando J., Korenaga R., Toyo-oka T., Kamiya A. Exogenous nitric oxide inhibits proliferation of cultured vascular endothelial cells. Biochem. Biophys. Res. Commun. 203:1994;1160-1167.
25. Xie K.P., Huang S.Y., Dong Z.Y., Juang S.H., Wang Y.F., Fidler I.J. Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene. J. Natl. Cancer Inst. 89(6):1997;421-427.
26. Lesoon-Wood L.A., Lau A.F., Cooney R.V. Inducible nitric oxide synthase : the use of antisense oligodeoxynucleotides to study its regulation and role in neoplastic transformation. Proc. Am. Assoc. Cancer Res. 37:1996;145.
27. Farias-Eisner R., Sherman M.P., Aeberhard E., Chaudhuri G. Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc. Natl. Acad. Sci. USA. 91:1994;9407-9411.
28. Jenkins D.C., Charles I.G., Thomsen L.L., Moss D.W., Holmes L.S., Baylis S.A., Rhodes P., Westmore K., Emson P.C., Moncada S. Roles of nitric oxide in tumor growth. Proc. Natl. Acad. Sci. USA. 92:1995;4392-4396.
29. Xie K., Huang S., Dong Z., Juang S.-H., Gutman M., Xie Q.-W., Nathan C., Fidler I.J. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J. Exp. Med. 181:1995;1333-1343.
30. Bani D., Masini E., Bello M.G., Bigazzi M., Sacchi T.B. Relaxin activates the L-arginine-nitric oxide pathway in human breast cancer cells. Cancer Res. 55:1995;5272-5275.
31. Forrester K., Ambs S., Lupold S.E., Kapust R.B., Spillare E.A., Weinberg W.C., Felley-Bosco E., Wang X.W., Geller D.A., Tzeng E., Bulliar T.R., Harris C.C. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc. Natl. Acad. Sci. USA. 93:1996;2442-2447.
32. Colletta A.A., Wakefield L.M., Howell F.V., van Roozendaal K.E.P., Danielpour D., Ebbs S.R., Sporn M.B., Baum M. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br. J. Cancer. 62:1990;405-409.
33. Butta A., MacLennan K., Flanders K.C., Sacks N.P.M., Smith I., McKinna M.D., Wakefield L.M., Sporn M.B., Baum M., Colletta A.A. Induction of transforming growth factor β1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res. 52:1992;4261-4264.
34. Grainger D.J., Weissberg P.L., Metcalfe J.C. Tamoxifen decreases the rate of proliferation of rat vascular smooth-muscle cells in culture by inducing production of transforming growth factor β Biochem. J. 294:1993;109-112.
35. Gilbert R.S., Herschman H.R. Transforming growth factor Beta differentially modulates the inducible nitric oxide synthase gene in distinct cell types. Biochem. Biophys. Res. Commun. 195:1993;380-384.
36. Goureau O., Lepoivre M., Becquet F., Courtois Y. Differential regulation of inducible nitric oxide synthase by fibroblast growth factors and transforming growth factor β in bovine retinal pigmented epithelial cells: inverse correlation with cellular proliferation. Proc. Natl. Acad. Sci. USA. 90:1993;4276-4280.
37. Lin J.-Y., Seguin R., Keller K., Chadee K. Transforming growth factor-β1 primes macrophages for enhanced expression of the nitric oxide synthase gene for nitric oxide-dependent cytotoxicity against Entamoeba histolytica. Immunology. 85:1995;400-407.
38. Vodovotz Y., Geiser A.G., Chesler L., Letterio J., Campbell A., Lucia M.S., Sporn M.B., Roberts A.B. Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor β1 null mouse. J. Exp. Med. 183:1996;2337-2342.
39. Williams G., Becker L., Bryant D., Willis S., Giroir B.P. Effects of transforming growth factor-β1 on nitric oxide synthesis by C2C12 skeletal myocytes. Am. J. Physiol. 270:1996;R145-R152.